

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces Significant Overall Survival Benefit for Kadcyra in HER2-Positive Early-Stage Breast Cancer

TOKYO, December 11, 2023 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release regarding Kadcyra to extend overall survival in the KATHERINE Phase 3 clinical trial for HER2-positive early breast cancer on December 8.

Please refer to the link below for details of the press release:

Roche's Kadcyra is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

<https://www.roche.com/media/releases/med-cor-2023-12-08b>

###